14 results about "Losartan" patented technology

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, done or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts ("TEVGs") in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

This invention relates to the field of biomedical materials and pharmaceutical formulations, disclosing an FH peptide-polydopamine-coated graphene oxide drug delivery system and its preparation and application. The system includes an RGD peptide-modified graphene oxide carrier, a polydopamine shell, and a drug loaded within the system. The polydopamine shell is surface-modified with an FH peptide. The drugs include docetaxel and losartan, with docetaxel loaded on the RGD peptide-modified graphene oxide carrier and losartan loaded in the FH peptide-modified polydopamine shell. This FH peptide-polydopamine-coated graphene oxide drug delivery system, through surface modification of graphene oxide with an RGD peptide and coating with a polydopamine shell, effectively shields against the potential cytotoxicity and blood incompatibility risks of unmodified graphene oxide. Compared to unmodified graphene oxide carriers, this system shows significantly improved compatibility at both normal and tumor cell levels, maintaining extremely high cell viability across a wide concentration range.

The present application belongs to the field of medicine and chemical industry, and relates to a method for purifying losartan. In the method, bisulfite or sulfite is used to remove color impurities of losartan, and the method has the advantages of mild treatment condition, short operation period, high decolorization efficiency and suitability for industrial production.

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, alone or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts (“TEVGs”) in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

The present invention relates to a pharmaceutical combination preparation comprising ezetimibe and losartan. When the pharmaceutical combination preparation is dissolved in a solution of pH 4.0 to 5.0 for 10 minutes, the amount of losartan dissolved is 5,700 µg or less, and the amount of ezetimibe dissolved is 270 µg or more. Dissolution in a solution of pH 4.0 to 5.0 is carried out under conditions of a temperature of 37°C and a paddle method of 50 rpm in 500 mL of acetate pH regulator in accordance with the United States Pharmacopeia for the preparation of a pharmaceutical combination comprising 20 mg of ezetimibe and 183 mg of losartan.

The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.

The present invention relates to the technical field of biomedicine and discloses use of a hypoxanthine derivative in the preparation of a drug for treating renal fibrosis and / or kidney disease. By assaying pharmacological activities of structurally modified and altered hypoxanthine derivatives for treating renal fibrosis and / or kidney disease, the pharmacological activities of such compounds were tested in animal disease models, and data on activities for preventing and treating renal fibrosis and / or kidney disease were provided. It is proven that the hypoxanthine derivatives have good activities, and the effects are significantly superior to those of clinically commonly used positive drugs nintedanib and losartan, and the effects are also significantly superior to those of hypoxanthine derivatives A, B, and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative of the present invention can provide a novel skeleton for the screening of novel compounds for the preparation of a drug for treating renal fibrosis and / or kidney disease.

This invention relates to the field of pharmaceutical analysis technology, specifically to a method for determining the concentration of the antihypertensive drug losartan in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS / MS). The mobile phase of the LC comprises an aqueous formic acid solution and acetonitrile; the elution program of the LC includes: 60-80% acetonitrile by volume in the mobile phase for 0-1.4 min; and a flow rate of 0.6-1 mL / min. This invention provides a highly efficient and accurate method for detecting losartan drug concentration, enabling precise determination of the losartan concentration in plasma and ensuring the accuracy and reliability of the data.

Disclosed herein is a ready-to-use, non-aqueous oral solution of losartan. Also disclosed herein is a method of preparing a ready-to-use, non-aqueous oral solution of losartan and its method of use.

The present application provides a preparation method of losartan, which comprises the following steps: reacting a nitrile intermediate shown as below with an azide reagent in a solvent, then adding an aqueous solution of an inorganic base selected from carbonates or bicarbonates to wash and separate an intermediate layer; and further separating the intermediate layer to obtain losartan. The azide ion after the reaction can be basically completely removed by using a conventional inorganic base solution, the removal effect is good, the preparation process is simple, the operation condition is mild and easy to control, and the method is suitable for large-scale industrial production.

The present invention relates to Losartan for use in the treatment of a fibrotic disease, characterized in that a dose of 0.4-1.4 mg / kg body weight of the human patient is administered daily, whereby the fibrotic disease is epidermolysis bullosa.

The invention relates to the technical field of biological medicines, and discloses an application of a hypoxanthine derivative in preparation of a medicine for treating renal fibrosis and / or nephropathy, and the pharmacological activity of the hypoxanthine derivative subjected to structure modification and transformation is detected to treat renal fibrosis and / or nephropathy. The pharmacological activity of the compound is tested in an animal disease model, and the data of the activity of preventing and treating renal fibrosis and / or nephropathy is provided, which proves that the compound has good activity, and the effect is obviously superior to that of clinically common positive drugs nintedanib and losartan; the effect is obviously superior to those of hypoxanthine derivatives A, B and C and other hypoxanthine derivatives in the prior art. The hypoxanthine derivative disclosed by the invention can provide a novel skeleton for screening a novel compound for preparing a medicine for treating renal fibrosis and / or nephropathy, and lays a theoretical foundation for developing a novel lead compound.

The application discloses a kind of optical magnetic visualization biological hybrid nanosystem and its preparation method and application, the optical magnetic visualization biological hybrid nanosystem includes platelet membrane and the tannic acid manganese complex of losartan loading wrapped in the platelet membrane;The optical magnetic visualization biological hybrid nanosystem of the application can promote the deep penetration of drug and immune cell, and realizes tumor targeted therapy using the biological tropism of platelet membrane, in addition, it can also provide visual tracking for precision targeted therapy by fluorescence imaging and magnetic imaging dual imaging mode.